TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline in HPV viral load assessment of target lesions by quantitative PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in wart size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the HPV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cohabitation status
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: New stroke event for 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Moderate-to-severe bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of trimethylamine N-oxide in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hypometabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hyperphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Benefit Rate (CBR, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin appearance and condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment-induced Anti-Insulin Antibody (TI-AIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Step activity monitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed 8 meter walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of BI 730357 in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of BI 730357 in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rancho Los Amigo Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of Commands
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Willingness to participate in telerehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in regional contractility (wall-motion score index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Conversion from MCI to Probable AD Dementia
Endpoint domain: Mortality/survival
Primary endpoint: Elimination rate of milrinone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glycohaemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of novel molecular characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Digestive regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Yearly Progression Rate of Atrophic Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent fertile female O.volvulus worms in nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QST score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PYY3-34 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-lives of PYY1-36 and PYY3-36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving CR or CRi With Induction Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Irritable Bowel Symptom Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Induced corneal refractive change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in severity of ischemic brain injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax of Sativex®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of Sativex®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) of Sativex®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First moderate/severe asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to First loss of asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Phenotypic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Limb Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Improvement in Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients With Improvement in Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Methamphetamine-negative urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention participant retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participation in intervention related phone calls
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in writing amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in writing velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline to Week 13 in AM Predose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participant Ratings for Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant Ratings for Usefulness of the Information Presented
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Ratings for Ease of Understanding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: cumulative incidence of aGVHD relapse at 3 months after transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Mean Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Change From Baseline in Investigators Global Assessment (IGA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: homolateral retinal and choroidal vascular density (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in Gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Patient Health Questionnaire-9 (PHQ9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With C. Acnes Bacterium Culture After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median Colony Forming Units (CFU) After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants in Each Group With Positive C. Acnes Cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median Colony Forming Units Per mL Treatment vs Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Diabetes Self-Management Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of warfarin related clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meal stimulated C-peptide (area under the curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oxygenation/blood flow to brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unaided distance LogMAR visual acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pdet at Qmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pdetmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Width of the nasal cavity and olfactory slots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometry of the nasal cavity and olfactory slots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Body Mass Index Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone microstructure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function capacity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25(OH) Vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total 5 Symptom Score (T5SS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Toxicity and safe tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: number & severity of migraine or migrainous headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Bone Diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost of botulinum toxin utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fractional anisotropy in brain white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in muscle diameter (hypertrophy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to first life-threatening event
Endpoint domain: Mortality/survival
Primary endpoint: Pain responses of preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responses in metabolic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: All causes of death
Endpoint domain: Mortality/survival
Primary endpoint: Contrast media volume usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of patients without progression
Endpoint domain: Mortality/survival
Primary endpoint: Changes in patients' clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in IL-6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity rankings of swallowing pathophysiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life ratings (SwalQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete closure of the study ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of gaps in the RAPID video
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-void Residual (PVR) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Urine Flow Rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine Voided Volume (Voiding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Acute Urinary Retention (AUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Index of preparation quality for the whole colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of tumors with TFE3 rearrangement identified by FISH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and toxicity assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in illicit drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression symptoms and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adherence to collateral psychiatric treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of alpha-1 Ab titer positive subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical Attachment Level (CAL) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity, specificity and accuracy of CEUS and EOB-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhalation technique score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Category of management recommendation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SBP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With First Complete Occlusion Within 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With First Partial Occlusion Within 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With First Cathflo Administration for Occlusion (Blockage) Within 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of women with recommended gestational weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postpartum weight retention at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parent preference
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: In-hospital 60 days mortality
Endpoint domain: Mortality/survival
Primary endpoint: Validity of compression ultrasound testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in semen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in sperm concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in total motility of sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: NIHSS's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ASIA impairment scale (ASIA's score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Confirmed Disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients cured by day 14
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of adverse events after the start of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: IgE tissue compartment distribution in nasal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Messenger ribonucleic acid (mRNA) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline development quotient (DQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline score of the Conners Early Childhood (Conners EC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CORE-10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in aortic stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in systolic and diastolic brachial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in carotid systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of endothelial microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the adherence intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the adherence intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Perinatal or neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: Serious neonatal morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Mortality or survival with severe neuro-morbidities at 5 years of age
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of digital and remote monitoring technologies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in tobacco cessation care delivery of the 5 A's
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of smokers receiving assistance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Everyday Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance-Based Skills Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLU and GLU/GLN ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Toxicity Associated With High-dose Busulfan and Etoposide
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity Associated With Aldesleukin Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in MRI ADC value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in mpMRI tumour volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in enhancement measured as KTrans value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Wound Closure Post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: neurological outcome (death; CPC: 5)
Endpoint domain: Mortality/survival
Primary endpoint: Inter spinal distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of MELD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose-response information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with artery stenosis after radial artery decannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: time taken to reach adequate mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time Until JBRS Reverts Back to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of dalbavancin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing a treatment emergent adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients without infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Final Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of follow-up visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of injections of prophylactic treatment realized
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nausea Assessment and Treatment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Antiemetic Drug Therapies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perception of Postoperative Nausea Management Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fluid Compartment Volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermoregulation (core temperature)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermoregulation (skin temperature)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermoregulation (thermal sensation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nurses Clinical Reasoning Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication Skills Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intracuff pressure of the endotracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes